NASDAQ:MCRB Seres Therapeutics - MCRB Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.69 +0.02 (+0.35%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$5.49▼$5.7150-Day Range$4.95▼$6.0952-Week Range$2.50▼$9.49Volume863,994 shsAverage Volume1.25 million shsMarket Capitalization$717.40 millionP/E RatioN/ADividend YieldN/APrice Target$16.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Seres Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside185.6% Upside$16.25 Price TargetShort InterestBearish6.20% of Shares Sold ShortDividend StrengthN/ASustainability-1.14Upright™ Environmental ScoreNews Sentiment1.06Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.08) to ($1.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector422nd out of 1,005 stocksPharmaceutical Preparations Industry194th out of 486 stocks 3.5 Analyst's Opinion Consensus RatingSeres Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.25, Seres Therapeutics has a forecasted upside of 185.6% from its current price of $5.69.Amount of Analyst CoverageSeres Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.20% of the outstanding shares of Seres Therapeutics have been sold short.Short Interest Ratio / Days to CoverSeres Therapeutics has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Seres Therapeutics has recently increased by 8.91%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSeres Therapeutics does not currently pay a dividend.Dividend GrowthSeres Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSeres Therapeutics has received a 71.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Seres Therapeutics is -1.14. Previous Next 3.9 News and Social Media Coverage News SentimentSeres Therapeutics has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Seres Therapeutics this week, compared to 1 article on an average week.Search Interest52 people have searched for MCRB on MarketBeat in the last 30 days. This is an increase of 940% compared to the previous 30 days.MarketBeat Follows5 people have added Seres Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seres Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.20% of the stock of Seres Therapeutics is held by insiders.Percentage Held by Institutions90.16% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Seres Therapeutics are expected to decrease in the coming year, from ($1.08) to ($1.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seres Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seres Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSeres Therapeutics has a P/B Ratio of 63.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Seres Therapeutics (NASDAQ:MCRB) StockSeres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.Read More Receive MCRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MCRB Stock News HeadlinesMarch 25, 2023 | americanbankingnews.comSeres Therapeutics (NASDAQ:MCRB) Shares Down 4.9% March 24, 2023 | americanbankingnews.comCanaccord Genuity Group Boosts Seres Therapeutics (NASDAQ:MCRB) Price Target to $15.00March 26, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 9, 2023 | finance.yahoo.comSeres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare ConferenceMarch 9, 2023 | finance.yahoo.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2022 Earnings Call TranscriptMarch 8, 2023 | markets.businessinsider.comWhere Seres Therapeutics Stands With AnalystsMarch 8, 2023 | finance.yahoo.comQ4 2022 Seres Therapeutics Inc Earnings CallMarch 7, 2023 | finance.yahoo.comSeres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue EstimatesMarch 26, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 7, 2023 | msn.comSeres Therapeutics GAAP EPS of -$2.31 misses by $0.15, revenue of $7.13M misses by $6.62MMarch 7, 2023 | finance.yahoo.comSeres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesMarch 6, 2023 | msn.comSeres Therapeutics Earnings PreviewFebruary 28, 2023 | finance.yahoo.comSeres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023February 27, 2023 | finance.yahoo.comSeres Therapeutics to Participate in Cowen 43rd Annual Health Care ConferenceFebruary 14, 2023 | finance.yahoo.comSeres Therapeutics’ Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPENFebruary 8, 2023 | finance.yahoo.comSeres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell TransplantationJanuary 28, 2023 | finance.yahoo.comSeres Therapeutics' (NASDAQ:MCRB) investors will be pleased with their respectable 70% return over the last three yearsJanuary 13, 2023 | finance.yahoo.comSeres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 5, 2023 | finance.yahoo.comSeres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study ProgressJanuary 4, 2023 | finance.yahoo.comSeres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare ConferenceJanuary 1, 2023 | forbes.comSeres TherapeuticsNovember 22, 2022 | finance.yahoo.comSeres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial StrategyNovember 10, 2022 | seekingalpha.comSeres Gets Closer To Good TimesNovember 8, 2022 | finance.yahoo.comSeres Therapeutics Third Quarter 2022 Earnings: Misses ExpectationsNovember 2, 2022 | seekingalpha.comSeres Therapeutics, Inc. (MCRB) Q3 2022 Earnings Call TranscriptOctober 27, 2022 | finance.yahoo.comSeres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022October 26, 2022 | finance.yahoo.comSeres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority ReviewSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MCRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MCRB Company Calendar Last Earnings11/10/2021Today3/26/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MCRB CUSIPN/A CIK1609809 Webwww.serestherapeutics.com Phone(617) 945-9626FaxN/AEmployees333Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.25 High Stock Price Forecast$25.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+185.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-250,160,000.00 Net Margins-3,509.50% Pretax Margin-3,509.50% Return on Equity-548.64% Return on Assets-79.81% Debt Debt-to-Equity Ratio4.69 Current Ratio2.28 Quick Ratio2.28 Sales & Book Value Annual Sales$7.13 million Price / Sales100.62 Cash FlowN/A Price / Cash FlowN/A Book Value$0.09 per share Price / Book63.22Miscellaneous Outstanding Shares126,080,000Free Float120,781,000Market Cap$717.40 million OptionableOptionable Beta2.70 Key ExecutivesEric D. ShaffPresident, Chief Executive Officer & DirectorMarcus ChapmanSenior Vice President-OperationsDavid A. ArkowitzEVP, Chief Financial & Accounting OfficerMatthew R. HennChief Scientific Officer & Executive VPBarbara McGovernVice President-Medical AffairsKey CompetitorsCymaBay TherapeuticsNASDAQ:CBAYPharming GroupNASDAQ:PHARViking TherapeuticsNASDAQ:VKTX89bioNASDAQ:ETNBPOINT Biopharma GlobalNASDAQ:PNTView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 6,646 shares on 3/23/2023Ownership: 0.025%Point72 Middle East FZEBought 10,812 shares on 2/16/2023Ownership: 0.009%Silverarc Capital Management LLCBought 7,929 shares on 2/15/2023Ownership: 0.301%MetLife Investment Management LLCSold 6,646 shares on 2/15/2023Ownership: 0.026%E Fund Management Co. Ltd.Bought 2,597 shares on 2/15/2023Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions MCRB Stock - Frequently Asked Questions Should I buy or sell Seres Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MCRB shares. View MCRB analyst ratings or view top-rated stocks. What is Seres Therapeutics' stock price forecast for 2023? 5 brokerages have issued 12-month price targets for Seres Therapeutics' shares. Their MCRB share price forecasts range from $12.00 to $25.00. On average, they anticipate the company's stock price to reach $16.25 in the next twelve months. This suggests a possible upside of 185.6% from the stock's current price. View analysts price targets for MCRB or view top-rated stocks among Wall Street analysts. How have MCRB shares performed in 2023? Seres Therapeutics' stock was trading at $5.60 at the beginning of the year. Since then, MCRB shares have increased by 1.6% and is now trading at $5.69. View the best growth stocks for 2023 here. When is Seres Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our MCRB earnings forecast. How were Seres Therapeutics' earnings last quarter? Seres Therapeutics, Inc. (NASDAQ:MCRB) posted its earnings results on Wednesday, November, 10th. The biotechnology company reported $0.72 earnings per share for the quarter, beating the consensus estimate of ($0.47) by $1.19. The biotechnology company earned $126.73 million during the quarter, compared to the consensus estimate of $7.12 million. Seres Therapeutics had a negative trailing twelve-month return on equity of 548.64% and a negative net margin of 3,509.50%. During the same period last year, the firm earned ($0.36) earnings per share. What ETFs hold Seres Therapeutics' stock? ETFs with the largest weight of Seres Therapeutics (NASDAQ:MCRB) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB). What other stocks do shareholders of Seres Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD). When did Seres Therapeutics IPO? (MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers. What is Seres Therapeutics' stock symbol? Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB." Who are Seres Therapeutics' major shareholders? Seres Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Eversept Partners LP (1.77%), Geode Capital Management LLC (1.28%), Point72 Asset Management L.P. (0.56%), Jennison Associates LLC (0.54%), Charles Schwab Investment Management Inc. (0.51%) and JPMorgan Chase & Co. (0.49%). Insiders that own company stock include David S Ege and Health Ltp Fund Ge Nutritional. View institutional ownership trends. How do I buy shares of Seres Therapeutics? Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Seres Therapeutics' stock price today? One share of MCRB stock can currently be purchased for approximately $5.69. How much money does Seres Therapeutics make? Seres Therapeutics (NASDAQ:MCRB) has a market capitalization of $717.40 million and generates $7.13 million in revenue each year. The biotechnology company earns $-250,160,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. How many employees does Seres Therapeutics have? The company employs 333 workers across the globe. How can I contact Seres Therapeutics? Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.serestherapeutics.com. The biotechnology company can be reached via phone at (617) 945-9626 or via email at ctanzi@serestherapeutics.com. This page (NASDAQ:MCRB) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.